Heron Therapeutics (NASDAQ:HRTX – Get Rating) is set to post its quarterly earnings results after the market closes on Monday, May 9th. Analysts expect Heron Therapeutics to post earnings of ($0.45) per share for the quarter.
Heron Therapeutics (NASDAQ:HRTX – Get Rating) last posted its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.05. Heron Therapeutics had a negative return on equity of 159.70% and a negative net margin of 255.58%. The firm had revenue of $20.66 million for the quarter, compared to the consensus estimate of $25.77 million. During the same quarter last year, the company earned ($0.68) earnings per share. The business’s revenue for the quarter was up .2% compared to the same quarter last year. On average, analysts expect Heron Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ HRTX traded down $0.20 during trading on Wednesday, hitting $4.55. The company had a trading volume of 21,421 shares, compared to its average volume of 1,751,093. The stock has a 50 day simple moving average of $5.56 and a 200 day simple moving average of $8.11. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.90 and a current ratio of 3.58. Heron Therapeutics has a 12 month low of $4.40 and a 12 month high of $18.80. The firm has a market capitalization of $464.74 million, a P/E ratio of -2.04 and a beta of 1.37.
Several research analysts have recently commented on the company. Zacks Investment Research downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 9th. Cantor Fitzgerald decreased their target price on Heron Therapeutics from $26.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 1st. Cowen decreased their target price on Heron Therapeutics from $31.00 to $13.00 in a research note on Tuesday, March 1st. Needham & Company LLC decreased their target price on Heron Therapeutics from $24.00 to $16.00 in a research note on Tuesday, March 1st. Finally, StockNews.com initiated coverage on Heron Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Heron Therapeutics presently has a consensus rating of “Hold” and an average target price of $18.46.
About Heron Therapeutics (Get Rating)
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- Get a free copy of the StockNews.com research report on Heron Therapeutics (HRTX)
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
- There Are Weeds In The Garden At Scotts Miracle-Gro
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- 3M Stock is Worth a Look Because of the Company it Keeps
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.